CTOs on the Move


 
Cibus is part of the multi-billion-dollar plant seed industry. Cibus leads the new era of high throughput gene editing technology that can develop plant traits precisely at a fraction of the time and cost of conventional breeding. Cibus is not a seed company. We are a technology company that uses gene editing to develop plant traits. Cibus licenses its traits to seed companies for royalties on seeds that use its traits. Cibus` target market is Productivity Traits” that improve yields, lower input costs such as chemicals and increase the sustainability and profitability of farming. We has a pipeline of six ...
  • Number of Employees: 250-1000
  • Annual Revenue: $10-50 Million
  • www.cibus.com
  • 6455 Nancy Ridge Drive
    San Diego, CA USA 92121
  • Phone: 858.450.0008

Executives

Name Title Contact Details

Funding

Cibus raised $70M on 06/26/2018

Similar Companies

Verdezyne

Verdezyne, Inc. is a Carlsbad, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Mapp Biopharmaceutical

Mapp Biopharmaceutical Inc is a Biotechnology company located in 6160 Lusk Blvd Ste C105, San Diego, California, United States.

Plexxikon

Plexxikon is a Berkeley, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

BioServe

BioServe is a Beltsville, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Vitro Biopharma

Vitro Biopharma, a publicly traded biotechnology firm (OTCQB:VODG), develops technology and products derived from adult stem cells and is currently focused on mesenchymal stem cells (MSCs). MSCs have numerous applications in treatment of a variety of medical conditions, including injuries or diseases of the joints, heart, kidney, liver and lung failure, MS, stroke, cancer, hearing loss, and various other regenerative medicine applications. MSCs may be derived from an individual patient, expanded and then transplanted back to that patient to treat injury or disease through regeneration or repair of specific cells. Vitro manufactures and distributes to global markets a series of products for use by scientists and companies developing clinical applications of MSCs. Our products include: a) Cell Culture Media -We offer various formulations of MSCs and primary cell cultures with numerous competitive advantages. b) Various Cell Lines -Our cell lines include Umbilical Cord Blood derived MSCs, Adipose derived MSCs, Fluorescent Labeled MSCs, Cancer Associated Fibroblasts (CAFs), and Differentiated MSCs c) Brain-Grow Technologies -Neurological and Inflammatory Biomarker Profiling and Nutraceutical Recovery Packages